Active Biotech Q2 2024: Both Myelofibrosis Studies Soon Recruiting - Redeye

Redeye comments on Active Biotech's Q2 report. New results with naptumomab + docetaxel were presented by NeoTX in the quarter, with inconclusive results. The US study in myelofibrosis is ready to recruit the first patient, while the European study is estimated to be ready to begin recruitment in Q3.

Länk till analysen i sin helhet: https://www.redeye.se/research/1033031/active-biotech-q2-2024-both-myelofibrosis-studies-soon-recruiting?utm_source=finwire&utm_medium=RSS